Stocks Health care ELOX
NASDAQ · Health careEloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. reported revenue of $0 in fiscal 2025, down 100.0% from a year earlier. It posted a net loss of $6M. At June 30, 2026 it held $62M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Eloxx Pharmaceuticals, Inc.
- Net worth
- Eloxx Pharmaceuticals, Inc. has a market value (market cap) of $54.5M at the latest share price, and shareholders' equity of $46.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $6M.
- Cash flow
- In fiscal 2025 operations used $6.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Eloxx Pharmaceuticals, Inc.'s next report was expected around October 23, 2026 and is not on file with the SEC yet.
What Eloxx Pharmaceuticals, Inc. does
Eloxx Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ELOX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$6M | -$0.49 | n/a |
| 2025 | $6.4M | -$3.1M | -$0.84 | n/a |
| 2023 | $0 | -$17.1M | -$6.63 | n/a |
| 2022 | n/a | -$36.1M | -$16.65 | -$31.9M |
| 2021 | n/a | -$66.7M | -$38.15 | -$35.1M |
| 2020 | n/a | -$34.6M | -$34.54 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Eloxx Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026IPO registration S-1
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026
- August 11, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 17, 2026Passive stake (5% or more) SCHEDULE 13G
- June 17, 2026Passive stake (5% or more) SCHEDULE 13G
- June 16, 2026Passive stake (5% or more) SCHEDULE 13G
- June 16, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Eloxx Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 10, 2026 | Domicilium Real Estate Fund III LP10% owner | Other changeindirect | 238,422 | - |
| June 10, 2026 | Domicilium Real Estate Fund III LP10% owner | Other changeindirect | 361,578 | - |
| May 27, 2026 | Domicilium Real Estate Fund III LP10% owner | Other change | 113,636 | - |
| May 27, 2026 | Coastlands Capital LP10% owner | Other changeindirect | 1,250,000 | - |
| February 28, 2026 | Aggarwal SumitPresident and CEO, Director, 10% owner | Exercised options | 260,946 | $39.1K |
| January 24, 2026 | Walts Alan EdmundDirector | Exercised options | 1,875 | - |
| January 24, 2026 | Aggarwal SumitPresident and CEO, Director, 10% owner | Exercised options | 15,000 | - |
| January 24, 2026 | Rubin Steven DDirector | Exercised options | 1,875 | - |
Who owns ELOX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Domicilium Capital Partners LLC13G, passive with 6 related filers | 19.99% | June 17, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 9.99% | June 17, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 9.99% | June 15, 2026 |
| Aberdeen Group plc13G, passive with 1 related filers | 9.91% | July 27, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.91% | August 14, 2026 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 9.9% | June 16, 2026 |
| Srinivas Akkaraju13G, passive with 4 related filers | 9.9% | August 14, 2026 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 9.9% | June 16, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 22 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 800,000 | new |
| EcoR1 Capital, LLC | 400,000 | new |
| Aberdeen Group plc | 400,000 | new |
| Samsara Biocapital, LLC | 400,000 | new |
| Siren, L.L.C. | 400,000 | new |
| Stonepine Capital Management, LLC | 397,160 | new |
| Vanguard Capital Management LLC | 78,680 | new |
| Vanguard Fiduciary Trust Co | 10,602 | new |
| Seven Grand Managers, LLC | 10,000 | new |
| Morgan Stanley | 1,544 | new |
| Vanguard Global Advisers, LLC | 718 | new |
| UBS Group AG | 637 | new |
| Wells Fargo & Company | 126 | new |
| Pioneer Family Office, LLC | 96 | new |
| Royal Bank of Canada | 98 | new |
| Altshuler Shaham Ltd | 25 | new |
| Barclays PLC | 12 | new |
| Towne Trust Company, N.A | 5 | new |
| Citigroup Inc | 4 | new |
| Activest Wealth Management | 4 | new |
Insiders
4 insiders reported holding 2,064,526 shares in total, about $27.9M at the last price.
| Holder | Shares |
|---|---|
| Aggarwal SumitPresident and CEO, Director, 10% owner | 1,672,756 |
| Domicilium Real Estate Fund III LP10% owner | 361,578361,578 held indirectly |
| Walts Alan EdmundDirector | 15,567 |
| Rubin Steven DDirector | 14,625 |
Questions about ELOX
What does Eloxx Pharmaceuticals, Inc. do?
Eloxx Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ELOX. Its shares trade on NASDAQ under the ticker ELOX.
What is Eloxx Pharmaceuticals, Inc.'s net worth?
Eloxx Pharmaceuticals, Inc. has a market value (market cap) of $54.5M at the latest share price, and shareholders' equity of $46.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Eloxx Pharmaceuticals, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $6M.
How much revenue does Eloxx Pharmaceuticals, Inc. make?
In fiscal 2025 Eloxx Pharmaceuticals, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Eloxx Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from September 11, 2026.
When is Eloxx Pharmaceuticals, Inc.'s next earnings report?
Eloxx Pharmaceuticals, Inc.'s next report was expected around October 23, 2026 and is not on file with the SEC yet.
Similar companies
Compare ELOX with
Follow ELOX
Get an email when Eloxx Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Eloxx Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.